首页> 外文期刊>Scandinavian journal of urology >Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy
【24h】

Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy

机译:诊断后一年且重复活检前应进行主动监测的前列腺癌患者的弥散加权磁共振成像

获取原文
获取原文并翻译 | 示例
       

摘要

Objective. The aim of this study was to evaluate prospectively whether diffusion-weighted magnetic resonance imaging (DW-MRI), interpreted in a routine clinical setting, can serve as a diagnostic and prognostic tool for prostate carcinoma patients on active surveillance (AS). Material and methods. Eighty men enrolled in the Finnish arm of the PRIAS (Prostate Cancer Research International: Active Surveillance) study were followed for at least 1 year and had DW-MRI scans taken in addition to repeat biopsy. Spearman's correlations were analysed between tumour appearance on DW-MRI and clinical variables [age, prostate-specific antigen (PSA), free PSA, PSA doubling time, prostate volume, percentage of cancer at diagnostic biopsy]. The Pearson chi-squared test clarified associations between outcome factors (number of positive cores and Gleason score on repeat biopsy, treatment change) and DW-MRI results. Assumed predictors of deferred radical treatment were examined with logistic regression analysis. Accuracy of tumour localization by DW-MRI compared to repeat biopsy findings was analysed by the chi-squared test. Results. DW-MRI revealed an anatomical lesion suggestive of cancer in 40 patients (50%). MRI positivity showed no significant correlation with clinical variables. No associations existed between tumour appearance on DW-MRI and biopsy findings or discontinuation of AS. The only variable predicting treatment change was higher PSA at discontinuation (p = 0.002). Appearance of tumour, either on T2-weighted MRI (p = 0.273) or on apparent diffusion coefficient maps (p = 0.691), was not a significant predictor of treatment change. Conclusions. Localized low-grade prostate cancer is challenging to visualize in DW-MRI, and this imaging technique provides no additional prognostic benefit compared to PSA and repeat biopsies.
机译:目的。这项研究的目的是前瞻性评估在常规临床环境中解释的弥散加权磁共振成像(DW-MRI)是否可以作为主动监测(AS)的前列腺癌患者的诊断和预后工具。材料与方法。随访了80名参加PRIAS(国际前列腺癌研究:主动监测)研究的芬兰人,至少进行了1年的随访,并进行了DW-MRI扫描和重复活检。 Spearman的相关性在DW-MRI上的肿瘤外观与临床变量[年龄,前列腺特异性抗原(PSA),游离PSA,PSA倍增时间,前列腺体积,诊断性活检时的癌症百分比]之间进行了分析。 Pearson卡方检验阐明了结果因素(重复活检,治疗改变时阳性核心数和Gleason评分)与DW-MRI结果之间的关联。用逻辑回归分析检查假定的延迟治疗的预测因素。通过卡方检验分析与重复活检结果相比,通过DW-MRI进行的肿瘤定位的准确性。结果。 DW-MRI显示40例患者(50%)的解剖学病变提示癌症。 MRI阳性与临床变量无显着相关性。在DW-MRI上出现的肿瘤与活检结果或AS停药之间没有关联。预测治疗改变的唯一变量是停药时较高的PSA(p = 0.002)。在T2加权MRI(p = 0.273)或表观扩散系数图(p = 0.691)上,肿瘤的出现不是治疗改变的重要预测指标。结论局限性低度前列腺癌在DW-MRI中难以可视化,并且与PSA和重复活检相比,这种成像技术没有提供更多的预后益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号